Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-06

Study Completion Date

2021-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be performed. Extensive biological- and immune-monitoring pre- and post-IL2 will contribute (i) to define the common or distinct processes responsible for the breakdown of immunological tolerance in these pathologies and (ii) to discover potential biomarkers of the IL2 response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers

NCT03837093

Healthy Volunteers

COMPLETED PHASE1

Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease

NCT03683498

Chronic Graft vs Host Disease

COMPLETED PHASE1

Remicade Infusion Management Program

NCT00723905

Crohn Disease Arthritis, Rheumatoid

COMPLETED

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT07123038

Rheumatoid Arthritis (RA) Hidradenitis Suppurativa (HS)

RECRUITING

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

NCT00076726

Giant Cell Arteritis

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Protocol: TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low doses IL2 across 14 selected pathologies: rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet's disease, Wegener's granulomatosis, Takayasu's disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis, sclerosing cholangitis, Gougerot-sjögren, Systemic Sclerosis and Idiopathic Thrombocytopenic Purpura. Methods: Each patient will receive 1MUI /day of IL2 from Day-1 to Day-5 (the induction period), and then every 2 weeks (except systemic lupus erythematosus's patients will received every week) from Day-15 to Day-180 (the maintenance period). Patients will thereafter be followed up for 12 months (Day-181-Day-540). For each pathology, 6 patients will be included at Pitié-Salpêtrière, Cochin, Saint Antoine, Paul Brousse and Henri Mondor hospitals in Paris and Créteil, France. An interim analysis will be performed in each pathology group when the first six patients have received at least 3 months of treatment. In those pathology groups in which a Treg response will be documented, six additional patients will be included. In total, a minimum of 84 patients and up to 132 patients will be enrolled in this study. Primary efficacy endpoint is the Treg response at Day-8 compared to baseline. Secondary efficacy endpoints are:- evolution of the Treg response during the maintenance period,- the changes in markers of inflammation - the clinical response, evaluated by means of global generic scales \[Clinical Global Impression severity scale (CGI-sev) and Clinical Global Impression efficacy index (CGI-eff)\] as well as specific clinical and biological evaluations for each disease, - the frequency of relapses, - the assessment of quality of life (scale EuroQL-5). Expected Results: TRANSREG will define which patients respond to IL2, whether per pathology or according to pre-treatment phenomics, allowing to guide further clinical development of low dose IL2 in autoimmune and auto-inflammatory diseases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis Ankylosing Spondylitis Systemic Lupus Erythematosus Psoriasis Behcet's Disease Wegener's Granulomatosis Takayasu's Disease Crohn's Disease Ulcerative Colitis Autoimmune Hepatitis Sclerosing Cholangitis Gougerot-sjögren Idiopathic Thrombocytopenic Purpura Systemic Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interleukin 2

Interleukin 2, 1MUI.= Proleukin®, RhIL-2

Group Type EXPERIMENTAL

Interleukin 2

Intervention Type DRUG

Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interleukin 2

Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 18 year
* male or female
* documented diagnosis of one AIID among the 14 diseases selected (following consensual specific criteria)
* stable or moderately active disease (except Lupus) under standard treatment (≥ 2 months) at the time of inclusion (except Sclerosing Cholangitis, Gougerot-sjögren, Takayasu's Disease and Systemic Sclerosis)
* normal thyroid function (with or without treatment)
* effective contraception for more than two weeks at inclusion and negative beta HCG test for women of childbearing potential,
* affiliated to the social security system
* written informed consent form.

Exclusion Criteria

* known intolerance for IL2 (see SPC),
* administration of a non-authorized treatment and/or IV bolus of corticosteroids in the last 2 months,
* vaccination with live attenuated virus in the months preceding the inclusion or planned during the study
* other severe or progressive autoimmune/inflammatory pathology,
* low white blood cell count\<2000/mm3, lymphocytes \<600/mm3, platelets \<80 000/mm3,
* heart failure (≥ grade III NYHA), renal insufficiency (Cockcroft\< 60ml/mn except patients with lupus or Wegener's granulomatosis) or hepatic insufficiency (transaminases\> 5N except for patients with autoimmune hepatitis), or lung failure,
* significant abnormality in chest X-ray other than these linked to the diseases under investigation
* cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)
* poor venous access not allowing repeated blood tests,
* restrictive diet or parenteral nutrition,
* surgery during the last 2 months or surgery planned during the study,
* participation in other biomedical research in the last 3 months or planned during the study.
* pregnant or lactating women,
* concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent,
* positive HIV serology, active hepatitis B or EBV infection,
* patients under a measure of legal protection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David KLATZMANN, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henri Mondor - Médecine Interne

Créteil, , France

Site Status

Médecine interne - Hôpital Saint-Antoine

Paris, , France

Site Status